Title: 404 URL Source: https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf Markdown Content: # 404 [Skip to main content](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#mainBody) This information is intended for US healthcare professionals. [Continue](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#)[VISIT PATIENT SITE](https://www.veklury.com/) * [Prescribing Information](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf) * [Important safety Information](https://www.vekluryhcp.com/important-safety-information) * [STAY INFORMED](https://www.vekluryhcp.com/register) * [CONTACT A REP](https://www.askgileadmedical.com/) * [Patient Site](https://www.veklury.com/) [![Image 1: VEKLURY® (remdesivir) brand name and logo](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/logo/veklury-remdesivir-logo-ko-blue-image.png?h=210&iar=0&w=372&hash=E5FF606398AFA96403E929EE6779ED95)](https://www.vekluryhcp.com/) Close main menu * [Home](https://www.vekluryhcp.com/) * [Why VEKLURY?](https://www.vekluryhcp.com/why-veklury) * [How VEKLURY Works](https://www.vekluryhcp.com/why-veklury) * [The Ongoing Need for VEKLURY](https://www.vekluryhcp.com/why-veklury/need-for-veklury) * [Inpatient Studies](https://www.vekluryhcp.com/inpatient) * [Mild, Moderate, or Severe COVID-19 (ACTT-1)](https://www.vekluryhcp.com/inpatient) * [Renal Impairment and COVID-19 (REDPINE)](https://www.vekluryhcp.com/inpatient/redpine-study) * [Pediatric Patients and COVID-19 (CARAVAN)](https://www.vekluryhcp.com/inpatient/pediatric) * [Severe COVID-19 (Study 5773)](https://www.vekluryhcp.com/inpatient/study-5773) * [Moderate COVID-19 (Study 5774)](https://www.vekluryhcp.com/inpatient/study-5774) * [Outpatient Study](https://www.vekluryhcp.com/outpatient) * [Real-World Studies](https://www.vekluryhcp.com/real-world-studies/readmission) * [Readmission Data](https://www.vekluryhcp.com/real-world-studies/readmission) * [Mortality Data](https://www.vekluryhcp.com/real-world-studies/mortality) * [VEKLURY and Corticosteroids](https://www.vekluryhcp.com/real-world-studies/dex) * [Dosing and Administration](https://www.vekluryhcp.com/dosing-and-admin) * [Access and Resources](https://www.vekluryhcp.com/resources) * [Resources](https://www.vekluryhcp.com/resources) * [Videos](https://www.vekluryhcp.com/videos) * [CONTACT A REP](https://www.askgileadmedical.com/) * [PRESCRIBING INFORMATION](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf) * [IMPORTANT SAFETY INFORMATION](https://www.vekluryhcp.com/important-safety-information) * [STAY INFORMED](https://www.vekluryhcp.com/register) * [PATIENT SITE ![Image 2: SC field](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/resources/external-document-icon.svg)](https://www.veklury.com/) * [![Image 3](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/social-icons/youtube-logo.png)](https://www.youtube.com/@VEKLURYhcp) * [![Image 4](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/social-icons/facebook-logo.png)](https://www.facebook.com/profile.php?id=61550712211294) * [![Image 5](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/social-icons/instagram-logo.png)](https://www.instagram.com/) ## Page Not Found (404) To find the content you are looking for, please use any of the links in the site map: * [Home](https://www.vekluryhcp.com/) * [Why VEKLURY?](https://www.vekluryhcp.com/why-veklury) * [How VEKLURY Works](https://www.vekluryhcp.com/why-veklury) * [The Ongoing Need for VEKLURY](https://www.vekluryhcp.com/why-veklury/need-for-veklury) * [Inpatient Studies](https://www.vekluryhcp.com/inpatient) * [Mild, Moderate, or Severe COVID-19 (ACTT-1)](https://www.vekluryhcp.com/inpatient) * [Renal Impairment and COVID-19 (REDPINE)](https://www.vekluryhcp.com/inpatient/redpine-study) * [Pediatric Patients and COVID-19 (CARAVAN)](https://www.vekluryhcp.com/inpatient/pediatric) * [Severe COVID-19 (Study 5773)](https://www.vekluryhcp.com/inpatient/study-5773) * [Moderate COVID-19 (Study 5774)](https://www.vekluryhcp.com/inpatient/study-5774) * [Outpatient Study](https://www.vekluryhcp.com/outpatient) * [Real-World Studies](https://www.vekluryhcp.com/real-world-studies/readmission) * [Readmission Data](https://www.vekluryhcp.com/real-world-studies/readmission) * [Mortality Data](https://www.vekluryhcp.com/real-world-studies/mortality) * [VEKLURY and Corticosteroids](https://www.vekluryhcp.com/real-world-studies/dex) * [Dosing and Administration](https://www.vekluryhcp.com/dosing-and-admin) * [Access and Resources](https://www.vekluryhcp.com/resources) * [Resources](https://www.vekluryhcp.com/resources) * [Videos](https://www.vekluryhcp.com/videos) * [Stay Informed](https://www.vekluryhcp.com/register) * [Contact a Rep](https://www.askgileadmedical.com/) ## Important Safety Information ## Important Safety Information and Indication [Back to Top](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) Tap for Important Safety Information, including contraindication for history of clinically significant hypersensitivity to VEKLURY. [](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#)[](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death. **Contraindication** * VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components. **Warnings and precautions** * **Hypersensitivity, including infusion-related and anaphylactic reactions:** Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most reactions occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time of up to 120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment (see Contraindications). * **Increased risk of transaminase elevations:** Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing VEKLURY if ALT levels increase to >10x ULN. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation. * **Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine:** Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of VEKLURY. **Adverse reactions** * The most common adverse reaction (≥5% all grades) was nausea. * The most common lab abnormalities (≥5% all grades) were increases in ALT and AST. **Dosage and administration** * Administration should take place under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. * **Treatment duration:** * For patients who **are hospitalized**, VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19. * For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days. * For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days. * For patients who are **not hospitalized**, diagnosed with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset for outpatient use. * **Testing prior to and during treatment:** Perform hepatic laboratory and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate. * **Renal impairment:** No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis. **Pregnancy and lactation** * **Pregnancy:** Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester. Maternal and fetal risks are associated with untreated COVID-19 in pregnancy. * **Lactation:** VEKLURY can pass into breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from an underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19. [](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) ## Indication VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death. **Please see full [Prescribing Information](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf) for VEKLURY.** ## Important Safety Information ## Important Safety Information and Indication [Back to Top](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) Tap for Important Safety Information, including contraindication for history of clinically significant hypersensitivity to VEKLURY. [](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#)[](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death. **Contraindication** * VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components. **Warnings and precautions** * **Hypersensitivity, including infusion-related and anaphylactic reactions:** Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of VEKLURY; most reactions occurred within 1 hour. Monitor patients during infusion and observe for at least 1 hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time of up to 120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue VEKLURY and initiate appropriate treatment (see Contraindications). * **Increased risk of transaminase elevations:** Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received VEKLURY; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing VEKLURY if ALT levels increase to >10x ULN. Discontinue VEKLURY if ALT elevation is accompanied by signs or symptoms of liver inflammation. * **Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine:** Coadministration of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of VEKLURY. **Adverse reactions** * The most common adverse reaction (≥5% all grades) was nausea. * The most common lab abnormalities (≥5% all grades) were increases in ALT and AST. **Dosage and administration** * Administration should take place under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. * **Treatment duration:** * For patients who **are hospitalized**, VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19. * For patients who are hospitalized and do not require invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended up to 5 additional days, for a total treatment duration of up to 10 days. * For patients who are hospitalized and require invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days. * For patients who are **not hospitalized**, diagnosed with mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days. VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 and within 7 days of symptom onset for outpatient use. * **Testing prior to and during treatment:** Perform hepatic laboratory and prothrombin time testing prior to initiating VEKLURY and during use as clinically appropriate. * **Renal impairment:** No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis. VEKLURY may be administered without regard to the timing of dialysis. **Pregnancy and lactation** * **Pregnancy:** Available clinical trial data for VEKLURY in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third-trimester exposure. There are insufficient data to evaluate the risk of VEKLURY exposure during the first trimester. Maternal and fetal risks are associated with untreated COVID-19 in pregnancy. * **Lactation:** VEKLURY can pass into breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VEKLURY and any potential adverse effects on the breastfed child from VEKLURY or from an underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19. [](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) ## Indication VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death. **Please see full [Prescribing Information](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf) for VEKLURY.** ## Contact a Representative [![Image 6: close-btn](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/modal/close-btn.svg?iar=0&hash=2166D6E8D447142FC6E0C95C4573DCA6)](https://www.vekluryhcp.com/-/media/project/vekluryhcp/pdf/veklury_prescribing_information.pdf#) ### Request contact from a VEKLURY® (remdesivir) representative Representatives are available to provide information and answer your questions via phone, video conference, and virtual events, as well as in person. Simply complete the form below. Your information will be used only to respond to your request and will not be used for any other purpose. You can also [register for updates](https://www.vekluryhcp.com/register/) to receive regular communications. All fields are required. [![Image 7: Gilead brand name and logo](https://www.vekluryhcp.com/-/media/project/veklury/vekluryhcp/logo/gilead-logo-ko-footer-image.svg?iar=0&hash=F84BDA0C714DCBBA552A8B3A76DE6796)](https://services.gileadhiv.com/gilead/links/gilead-site) * [Terms of Use](https://www.gilead.com/terms) * [Privacy Policy](https://www.gilead.com/privacy-statements/consumer-health-data-privacy-policy) * [Consumer Health Data Privacy Policy](https://www.gilead.com/privacy-statements/consumer-health-data-privacy-policy) * [Contact Us](https://services.gileadhiv.com/gilead/links/gilead-contact) * [Site Map](https://www.vekluryhcp.com/sitemap) * [Prescribing Information](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf) The information on this site is intended for audiences 18 years of age or older in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries. VEKLURY, the VEKLURY Logo, ADVANCING ACCESS, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks referenced herein are the property of their respective owners. © 2025 Gilead Sciences, Inc. All rights reserved. US-VKYP-0932 11/25 ![Image 8](https://px.deepintent.com/pixel.gif?id=65684b7234) We may utilize tracking technologies such as cookies and pixels to process personal data in order to enhance your experience on our site and to analyze performance and traffic. You may exercise your consumer right to opt-out by clicking the “Cookies Settings” link. For further information about the data we may collect, please see our[Cookie Policy.](https://www.gilead.com/privacy-statements/cookie-statement) Cookies Settings Reject All Allow All ![Image 9: Company Logo](https://cdn.cookielaw.org/logos/bf68afa0-3c8d-4d2e-9472-6b54f14f5822/d513e377-2af9-4a8a-b1d3-6d6d76674030/2b260913-9721-4f2a-897f-ca50399ed98a/Gilead_Logo_standard_RGB.png) ## Privacy Preference Center ## Privacy Preference Center * ### Your Privacy * ### Strictly Necessary Cookies * ### Performance Cookies * ### Targeting & Social Media Cookies * ### Functional Cookies #### Your Privacy When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.) #### Strictly Necessary Cookies Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, however if you do so, some parts of the site will not work. #### Performance Cookies - [x] Performance Cookies These cookies allow us to count visits, collect analytics, and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. In certain countries prior to banner acceptance, performance cookies may be sent to your browser. You may clear these cookies in your browser settings so that we will not know when you have visited our site and will not be able to monitor its performance. #### Targeting & Social Media Cookies - [x] Targeting & Social Media Cookies **Targeting Cookies** These cookies allow us to count visits, collect analytics and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. In certain jurisdictions prior to banner acceptance, performance cookies may be sent to your browser. They can track your browser across other sites and build a profile of your interests. They may impact the content and messages you see on other websites you visit. You may clear these cookies in your browser settings so that we will not know when you have visited our site and will not be able to monitor its performance. **Social Media Cookies** These cookies are set by social media services that we may have added to the site to enable you to share our content with your friends and social or professional networks. They can track your browser across other sites and build a profile of your interests. They may impact the content and messages you see on other websites you visit. #### Functional Cookies - [x] Functional Cookies These cookies enable the site to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly. ### Cookie List Consent Leg.Interest - [x] checkbox label label - [x] checkbox label label - [x] checkbox label label Clear * - [x] checkbox label label Apply Cancel Confirm My Choices Reject All Allow All [![Image 10: Powered by Onetrust](https://cdn.cookielaw.org/logos/static/powered_by_logo.svg)](https://www.onetrust.com/solutions/consent-and-preferences/?utm_source=cmp&utm_medium=cmpbanner)